Tag #Pharmaceutical Industry

Showing 133 to 144 of 152 results

forbes.com

🌐 85% Global Worthiness

Jan 19, 19:10

FTC Accuses PBMs of \$8.7 Billion in Price Gouging

The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...

FTC Accuses PBMs of \$8.7 Billion in Price Gouging

The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...

Progress

24% Bias Score

ShareSaveArticle

No Poverty

12345678

Previous 1 of 8 Next

What are the immediate, quantifiable effects of PBM pricing practices on patient costs and the overall pharmaceutical market?

The FTC's report accuses Pharmacy Benefit Managers (PBMs) of significantly increasing specialty generic drug prices, exceeding acquisition costs by over \$7.3 billion from 2017-2022 and using spread pricing to generate an additional \$1.4 billion. This practice, coupled with preferential reimbursement to affiliated pharmacies, directly increases patient out-of-pocket costs and contributes to rising pharmaceutical expenses.

cnbc.com

🌐 85% Global Worthiness

Jan 14, 22:08

Eli Lilly Stock Tumbles Despite Positive 2025 Outlook

Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...

Eli Lilly Stock Tumbles Despite Positive 2025 Outlook

Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What caused Eli Lilly's stock to plummet on Tuesday, and what are the immediate consequences of this decline?

Eli Lilly's stock dropped over 7% on Tuesday due to lowered 2024 revenue projections, primarily caused by underperforming sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound. The shortfall, approximately $400 million below expectations, resulted in a revised revenue outlook of around $13.5 billion for the fourth quarter, missing Wall Street estimates by $400 million.

nos.nl

🌐 85% Global Worthiness

Jan 9, 16:11

Netherlands Faces Persistent Medicine Shortages Affecting Millions

Over 4.5 million people in the Netherlands faced medicine shortages in 2024, with 193 life-saving drugs unavailable, including salbutamol inhalers, due to manufacturer production problems, logistical issues from Suez Canal disruptions, and insufficient market incentives.

Netherlands Faces Persistent Medicine Shortages Affecting Millions

Over 4.5 million people in the Netherlands faced medicine shortages in 2024, with 193 life-saving drugs unavailable, including salbutamol inhalers, due to manufacturer production problems, logistical issues from Suez Canal disruptions, and insufficient market incentives.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the underlying causes of the persistent medicine shortages in the Netherlands?

The medicine shortages are attributed to several factors: preferential policies by insurers limiting medicine choices, production problems at manufacturers, logistical issues due to the Suez Canal disruptions, and a lack of market attractiveness for manufacturers in the Netherlands. These issues resulted in shortages of 669 essential medicines, potentially causing patient death or increased illness within 3 months.

forbes.com

🌐 85% Global Worthiness

Jan 2, 22:08

Defeated PBM Reform Bill Fails to Address Core Issues

The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.

Defeated PBM Reform Bill Fails to Address Core Issues

The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the rebate system within the PBM model contribute to higher costs for patients and inequities among businesses?

While the proposed legislation in HR II Section 227 shifted rebates to plan sponsors, it maintained the problematic rebate system, distorting drug selection away from patient value and towards profit maximization. This system leads to higher enrollee costs and inequities for small businesses, who receive no rebate share.

cincodias.elpais.com

🌐 75% Global Worthiness

Dec 25, 10:06

Novo Nordisk Stock Plummets 40% on CagriSema Trial Results

Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...

Novo Nordisk Stock Plummets 40% on CagriSema Trial Results

Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary driver behind Novo Nordisk's significant stock price decline, and what are the immediate consequences?

Novo Nordisk's stock has plummeted 40% from its June peak due to market correction of its Ozempic and Wegovy obesity drugs. These drugs, along with Eli Lilly's offerings, caused a market revolution, achieving 15-20% weight loss. However, uncertainties remain regarding long-term effects and potential rebound effects for repeat users.

cnn.com

🌐 85% Global Worthiness

Dec 22, 01:07

Congress Fails to Pass PBM Reform

Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...

Congress Fails to Pass PBM Reform

Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What specific practices of PBMs are under scrutiny, and how would the proposed reforms have addressed these concerns?

The failed PBM reform legislation would have mandated more transparency in PBM operations, including their drug pricing and rebate negotiations. It also sought to shift compensation models away from those potentially incentivizing higher-cost drugs. Opposition from the PBM industry and the bill's removal from the funding package highlight the significant political influence of PBMs and the challenges in reforming the industry.

bbc.com

🌐 85% Global Worthiness

Jan 15, 19:10

Iran's Medicine Crisis: Price Hikes, Shortages, and Hospital Thefts

Due to reduced government subsidies, a rise in the dollar's exchange rate, and raw material shortages, medicine prices in Iran have sharply increased, causing shortages, hospital drug thefts, and endangering patients; the government's debt to the pharmaceutical industry and insurance companies furth...

Iran's Medicine Crisis: Price Hikes, Shortages, and Hospital Thefts

Due to reduced government subsidies, a rise in the dollar's exchange rate, and raw material shortages, medicine prices in Iran have sharply increased, causing shortages, hospital drug thefts, and endangering patients; the government's debt to the pharmaceutical industry and insurance companies furth...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the primary causes of the significant price increases and shortages of essential medicines in Iran, and what are the immediate consequences for patients?

The price of medicine in Iran has drastically increased, with some drugs seeing price hikes of several hundred percent. This is due to a combination of factors, including reduced government subsidies, a rise in the exchange rate of the dollar, and a shortage of raw materials. Reports indicate that this has led to the theft of cancer and chemotherapy drugs from hospitals, endangering patients.

nrc.nl

🌐 85% Global Worthiness

Jan 9, 01:10

Galapagos Restructures, Splits into Two, Cuts 300 Jobs

Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...

Galapagos Restructures, Splits into Two, Cuts 300 Jobs

Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the restructuring impact Galapagos' financial standing and future strategic direction?

The restructuring aims to address Galapagos' poor performance and investor skepticism regarding its use of capital. SpinCo will use the funding for acquisitions of smaller biotech companies, while Galapagos retains \u20ac500 million for its cell therapy operations. This move also frees Galapagos from a restrictive 2019 agreement with Gilead Sciences, which limited its actions.

china.org.cn

🌐 85% Global Worthiness

Jan 3, 19:10

China's Plan to Reform Pharmaceutical Industry and Become Global Powerhouse by 2035

China issued a guideline to reform drug and medical device regulations, aiming to become a global pharmaceutical leader by 2035, involving 24 measures across five key areas to improve innovation, review efficiency, supervision, opening up and regulatory systems; by 2027, it aims to enhance legal fra...

China's Plan to Reform Pharmaceutical Industry and Become Global Powerhouse by 2035

China issued a guideline to reform drug and medical device regulations, aiming to become a global pharmaceutical leader by 2035, involving 24 measures across five key areas to improve innovation, review efficiency, supervision, opening up and regulatory systems; by 2027, it aims to enhance legal fra...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What specific steps is China taking to become a leading pharmaceutical innovator by 2035?

China's new guideline aims to transform its pharmaceutical industry into a global powerhouse by 2035, focusing on improving regulatory efficiency and innovation. This involves streamlining drug and medical device approvals, enhancing data protection, and prioritizing urgently needed treatments.

spanish.china.org.cn

🌐 75% Global Worthiness

Dec 25, 07:05

China Tightens Business Inspections, Reforms Pharmaceutical Regulations

The Chinese State Council approved a guideline to strictly regulate administrative inspections of businesses and reform drug and medical device regulations to promote high-quality development of the pharmaceutical industry, addressing arbitrary actions affecting business operations and market expect...

China Tightens Business Inspections, Reforms Pharmaceutical Regulations

The Chinese State Council approved a guideline to strictly regulate administrative inspections of businesses and reform drug and medical device regulations to promote high-quality development of the pharmaceutical industry, addressing arbitrary actions affecting business operations and market expect...

Progress

36% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

How will the reforms to drug and medical device regulations affect market stability and business operations in China?

This move aims to stabilize market expectations and improve law-based governance in China's pharmaceutical sector. The focus is on streamlining regulations, increasing efficiency, and promoting high-quality development of the industry, addressing concerns about arbitrary inspections that hinder business operations.

cnbc.com

🌐 85% Global Worthiness

Dec 23, 22:08

Eli Lilly Stock Soars on Obesity Drug Success

Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...

Eli Lilly Stock Soars on Obesity Drug Success

Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Eli Lilly addressing current supply chain challenges, and what are the long-term strategic implications of these actions?

The company's strategic investments in manufacturing capacity, coupled with efforts to alleviate drug shortages, underscore long-term confidence in the GLP-1 market. This proactive approach strengthens Eli Lilly's competitive position and positions it for sustained growth.

cincodias.elpais.com

🌐 65% Global Worthiness

Dec 19, 13:11

Rovi Expands Audit Reports Following CNMV Requirements on Sustainability

Following a CNMV request, Laboratorios Rovi expanded its audit reports to address climate change mitigation, ESG objectives, alternative performance measures, ethical channels, and water usage in its Alcalá de Henares and San Sebastián de los Reyes plants, with plans to update the ESG plan in 2025.

Rovi Expands Audit Reports Following CNMV Requirements on Sustainability

Following a CNMV request, Laboratorios Rovi expanded its audit reports to address climate change mitigation, ESG objectives, alternative performance measures, ethical channels, and water usage in its Alcalá de Henares and San Sebastián de los Reyes plants, with plans to update the ESG plan in 2025.

Progress

32% Bias Score

ShareSaveArticle

Climate Action

12345678

Previous 1 of 8 Next

How does Rovi's response to the CNMV's request regarding its ethical channels reveal its approach to risk management and transparency?

CNMV's requests addressed Rovi's ESG plan, alternative performance measures (APM), ethical channels, and water usage. Rovi is updating its 2023-2025 ESG plan in 2025, incorporating stakeholder feedback. The company clarified its APM approach and water management practices, emphasizing the critical role of water in its pharmaceutical production.

Showing 133 to 144 of 152 results